Northern Trust
TRAX

Northern Trust’s First Tracks Biotherapeutics TRAX Stock Holding History

Northern Trust’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.05M Buy
+201,096
New +$3.76M ﹤0.01% 2737

Other funds holding TRAX

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Northern Trust's TRAX Position: Q2 2026 in Review

Northern Trust opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 201,096 shares worth $4.05M. The stake represents ﹤0.01% of the portfolio and ranks #2737 among its holdings.

89 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Northern Trust held 201,096 shares of First Tracks Biotherapeutics worth $4.05M as of Q2 2026.
  • First Tracks Biotherapeutics was a new Northern Trust position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #2737 holding.
  • 89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.